Skip to main content
. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 5a. Comparison of treatment guidelines for treatment naïve patients infected with HCV genotypes 5 and 6.

AASLD/IDSA EASL WHO# APASL

  • Sofosbuvir/velpatasvir (I-A)

  • Sofosbuvir/ledipasvir(IIa-B)

  • PegIFN-α/RBV/sofosbuvir (B1)

  • Sofosbuvir/ledipasvirabc (B1)

  • Sofosbuvir/daclatasvirab (B1)

  • Sofosbuvir/ledipasvirab

Alternative

  • PegIFN-α/RBV/sofosbuvir

  • Sofosbuvir/velatasvir (A1) in cirrhosis (B1)

  • Sofosbuvir/ledipasvira (B1)

  • Sofosbuvir/daclatasvirab (B1)
*

If the platelet count is <75 × 103/μL, then 24 weeks of treatment with RBV should be given;

#

All regimens: conditional recommendation, very low quality of evidence.

a

24 weeks in patients with cirrhosis;

b

12 weeks with RBV in patients with cirrhosis;

c

24 weeks with RBV if negative predictors of response.

Abbreviations: PegIFN, Pegylated interferon; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.